# Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF

**Authors:** Patrick A. Kwaah, Samuel A. Mensah, Abraham Carboo, Hamza A. Rashid, Emmanuel A. Agyemang, Grace Appah, Smith K. Frimpong

PMC · DOI: 10.1016/j.jacadv.2025.101857 · JACC: Advances · 2025-06-03

## Full-text entities

- **Diseases:** Type II Diabetes (MESH:D003924)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12172265/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12172265/full.md

---
Source: https://tomesphere.com/paper/PMC12172265